Novo Nordisk explores hair-loss market expansion beyond GLP-1s

Novo Nordisk is exploring the hair-loss market to diversify beyond its GLP-1 drugs. Chief Scientific Officer Martin Lange said the company could leverage its scientific expertise, though it has not decided.